Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Earnings for Adial Pharmaceuticals, Inc. (ADIL)
Earnings in 2023 (TTM): $-7,001,890
According to Adial Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-7,001,890. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Adial Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-7,001,890 | $-7,001,890 |
| 2022 | $-12,731,918 | $-12,731,416 |
| 2021 | $-19,517,403 | $-19,423,326 |
| 2020 | $-10,892,990 | $-10,860,495 |
| 2019 | $-8,591,429 | $-8,591,429 |
| 2018 | $-11,631,378 | $-11,631,378 |
| 2017 | $-1,139,456 | $-1,139,456 |
| 2016 | $-420,200 | $-420,200 |
| 2015 | $-817,993 | $-817,993 |